High-Precision Reagents for Thyroid Hormone Inactivation Research and Oncology Applications. Deiodinase 3 (DIO3) is a selenocysteine enzyme that inactivates T4/T3, driving tumor-adaptive hypothyroidism and tissue regeneration. This guide provides an integrated market intelligence, preclinical progress, and validated assay tools for DIO3 drug discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DIO3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DIO3 Recombinant Protein (Catalytic Domain) Contains essential selenocysteine active site; Sequence Verified; High purity (>95%); HEK293-expressed (SECIS-competent); Endotoxin <1 EU/µg |
View DIO3 Products |
| Gene Delivery | DIO3 Lentivirus Premade Particles / Promise-ORF Full-length ORF with UGA recoding for stable cell line generation; critical for membrane-associated enzyme studies. |
View DIO3 Products |
| Benchmark Ab | Anti-DIO3 Reference Antibody (Research Grade) Recombinant positive control for western blot, IHC, and screening assays. |
View DIO3 Products |
| Validator | DIO3 siRNA Set (3 unique sequences) For knockdown verification and specificity controls in deiodination assays. |
View DIO3 Products |
| Selectivity Screen A | DIO1 Recombinant Protein (Type I deiodinase) Paralogue enzyme for off-target liability screening; crucial for avoiding systemic hyperthyroidism. |
View DIO1 Products |
| Selectivity Screen B | DIO2 Recombinant Protein (Type II deiodinase) Compensatory deiodinase for pathway redundancy and selectivity profiling. |
View DIO2 Products |
| Pathway Partner | THRB (Thyroid Hormone Receptor Beta) Downstream signaling node; resistance mechanism studies and functional readout for T3 signal restoration. |
View THRB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selenocysteine incorporation fidelity (UGA codon recoding) | HEK293 expression system with native SECIS element support; Sequence Verified for selenocysteine active site integrity |
| Isoform selectivity (DIO1/DIO2 off-target liability) | Complete deiodinase panel (DIO1, DIO2, DIO3) available with >95% purity; Sequence Verified identity for strict counter-screening |
| Membrane-associated enzyme activity & cell-based assays | Lentivirus-delivered stable lines preserve ER membrane localization for native conformational assays; Premade Lentivirus for HEK293/CHO stable cell line generation |
| Cross-species preclinical translation | Human / Mouse / Cyno DIO3 ortholog proteins available with theoretical MW confirmed (>95% purity) for species-relevant pharmacology |
| False positives in HTS & lack of reliable controls | Validated DIO3 siRNA included for orthogonal specificity checks; Sequence Verified recombinant benchmark antibodies for assay normalization |
Live DIO3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of DIO3 inhibition is rapidly shifting from classical endocrinology (consumptive hypothyroidism in infantile hemangioma) to oncology and regenerative medicine. In solid tumors, DIO3 overexpression creates a localized "hypothyroid" state that blocks T3-mediated differentiation, promotes proliferation, and contributes to immune evasion. As an oncofetal marker in hepatocellular carcinoma, colorectal cancer, and glioblastoma, DIO3 represents a compelling target. First-generation small-molecule inhibitors are entering preclinical development, while the next wave includes brain-penetrant compounds for glioblastoma, tissue-specific siRNA/ASO knockdown modalities, and PROTAC-based degradation to restore local T3 signaling without triggering systemic deiodinase compensation. The field is actively differentiating between unsafe pan-deiodinase inhibitors and DIO3-selective compounds. In regenerative medicine, transient DIO3 inhibition is being explored for beta-cell proliferation and wound healing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, emerging biotech, discovery-stage labs | Solid tumors (colorectal, breast), glioblastoma, hepatocellular carcinoma, consumptive hypothyroidism | Selectivity panel (DIO1/DIO2/DIO3) with high-purity selenoproteins; enzymatic inhibition assay (HPLC/LC-MS) |
| siRNA / ASO | Gene silencing specialists, rare disease-focused pharma, early discovery platforms | Hepatocellular carcinoma, solid tumors (oncofetal expression), hepatic hemangioma | DIO3 Lentivirus for stable cell model generation; cellular knockdown validation with validated siRNA |
| PROTAC / Degrader | Emerging PROTAC startups | Oncology (various), regenerative medicine | Cell-based target engagement assays using full-length DIO3 lentivirus cell lines; binding assays with high-purity native protein |
| Regenerative Medicine (transient inhibition) | Diabetes research institutes, wound healing research groups | Islet regeneration, wound healing | Cell-based T3/rT3 conversion assays using lentivirus-expressed DIO3 |
Future Directions & Strategic Considerations
Key trends over the next 3–5 years include: (1) isoform-selective inhibitors as the only viable path, requiring strict DIO1/DIO2 counter-screening; (2) BBB penetration as a differentiator for glioblastoma vs. peripheral selectivity for tumors; (3) combination therapy with immune checkpoint inhibitors to reverse metabolic immune suppression; and (4) early monitoring of compensatory upregulation of DIO1/DIO2 as a resistance mechanism. TarMart's rationally designed products—SECIS-competent HEK293-expressed proteins, lentivirus for membrane-anchored cell lines, and full deiodinase panels—directly address these strategic needs.